Bahija Jallal, Ph. D.
Bahija Jallal, Ph.D. has served as a member of Guardant Health’s board of directors since April 2019. Dr. Jallal has been the Chief Executive Officer and Director of Immunocore Limited since January 2019. Prior to Immunocore Limited, from October 2013 to January 2019, Dr. Jallal served as Executive Vice President of AstraZeneca PLC and President of MedImmune, a subsidiary of AstraZeneca, since January 2013. She joined MedImmune in 2006 and held various research and development positions, including Senior Vice President, Research and Development, from 2010 to 2013. She joined MedImmune in 2006 from Chiron Corporation where she served as Vice President of Drug Assessment and Development. Dr. Jallal has authored more than 70 peer-reviewed publications and holds more than 15 patents. She has been a member of the boards of directors of Immunocore Limited since January 2019 and of Anthem, Inc. since February 2018. Additionally, she is a member of the of the Board of Trustees of Johns Hopkins University and UMB Health Sciences Research Park Corporation and Past President of the Association for Women in Science. Dr. Jallal received her Ph.D. in physiology from the University of Pierre & Marie Curie in Paris, France and M.S. in Biology from the Universite de Paris VII in France. She conducted her postdoctoral research at the Max Planck Institute of Biochemistry in Martinsried, Germany.
AmirAli Talasaz, Ph.D.
President and Chief Operating Officer, Chairman of the Board
AmirAli Talasaz, Ph.D. is the co-founder and chairman of the board of directors for Guardant Health and has served as the President and Chief Operating Officer since January 2013. Prior to founding Guardant, Dr. Talasaz held various positions at Illumina, including Senior Director of Diagnostics Research from October 2011 to June 2012, where he led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. In March 2008, he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by lllumina in 2009. During his academic years, he led the Technology Development group at SGTC. He received his Ph.D. degree in electrical engineering, M.S. degree in electrical engineering and M.S. degree in management science and engineering from Stanford University.
Lead Independent Director
Ian Clark has served as a member of the board of directors for Guardant Health since December 2016. Mr. Clark currently serves as Guardant’s Lead Independent Director and serves on the boards of directors of Corvus Pharmaceuticals, Inc., Shire Pharmaceuticals, Inc. and other privately-held companies, including Forty Seven, Inc. He is also a member of Forty Seven, Inc.’s audit committee, and he served on the board of directors and audit committee of Kite Pharma, Inc. from January 2017 to October 2017. He served as Chief Executive Officer of Genentech Inc., or Genentech, from January 2010 to December 2016. Prior to that, he was the Executive Vice President and Chief Marketing Officer of the Roche Group, or Roche, from April 2009 to December 2009. Prior to his time at Roche, Mr. Clark held several senior management positions at Genentech from January 2003 to March 2009, including Head of Global Product Strategy, Chief Marketing Officer, Senior Vice President, General Manager of BioOncology and Executive Vice President, Commercial Operations. Before joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Ivax Pharmaceuticals, Inc. and Sanofi S.A. in the United Kingdom, France and Eastern Europe. He started his career at G.D. Searle, LLC, a subsidiary of Monsanto Corporation, holding positions in sales and marketing. Mr. Clark received a B.S. degree in Biology from South Hampton University.
Member of the Audit Committee
Chair of the Compensation Committee
Helmy Eltoukhy, Ph.D.
Chief Executive Officer and Director
Helmy Eltoukhy, Ph.D. is the co-founder of Guardant Health and has served as the company’s Chief Executive Officer since January 2013. Prior to founding Guardant, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007, he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008. He joined the Stanford Genome Technology Center, or SGTC, as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.
Aaref Hilaly has served as a member of Guardant Health’s board of directors since April 2015. Mr. Hilaly joined Sequoia Capital, a venture capital firm, in April 2012 and served as a Managing Member of Sequoia Capital Operations, LLC from January 2015 to June 2018. He currently serves on the board of directors of MobileIron, Inc. and a number of privately-held companies, including Clari, Inc. and ThousandEyes, Inc. Prior to joining Sequoia Capital, Mr. Hilaly served as Vice President, Engineering at Symantec Corp. from June 2011 to April 2012. He was the Chief Executive Officer of Clearwell Systems, Inc., or Clearwell, a provider of analytics software for electronic discovery, from April 2005 until Clearwell’s acquisition by Symantec in June 2011. Prior to that, Mr. Hilaly was the founder and Chief Executive Officer of CenterRun, Inc., a pioneer in datacenter automation, which was acquired by Sun Microsystems, Inc. Mr. Hilaly holds an M.B.A. degree from Harvard Business School, an M.A. degree in Economics from McGill University and a B.A. degree from Oxford University.
Member of the Compensation Committee
Samir Kaul has served as a member of Guardant Health’s board of directors since April 2014. Mr. Kaul has been a General Partner at Khosla Ventures, a venture capital firm focusing on technology investing, since February 2006 and currently serves on the boards of directors of several private companies. He also served as a member of the board of directors of Gevo, Inc. from March 2013 to May 2014 and Amyris, Inc. from May 2006 to May 2012. Previously, Mr. Kaul was a member of Flagship Pioneering Inc., a venture capital firm, from June 2002 to May 2006. Prior to that, Mr. Kaul worked at the Institute for Genomic Research. Mr. Kaul holds a B.S. degree in Biology from the University of Michigan, an M.S. degree in Biochemistry from the University of Maryland and an M.B.A. degree from Harvard Business School.
Member of the Audit Committee
Chair of the Nominating and Corporate Governance Committee
Stanley Meresman has served as a member of Guardant Health’s board of directors since May 2018. During the last ten years, Mr. Meresman has served on the boards of directors of various public and private companies, including service as chair of the audit committee for some of these companies. He currently serves on the board of directors, and as chair of the audit committee, of Snap, Inc. Previously, he served as a member of the board of directors, and chair of the audit committee, of Palo Alto Networks, Inc. from December 2014 to December 2018, LinkedIn Corporation from October 2010 to December 2016, Zynga Inc. from June 2011 to June 2015, Meru Networks, Inc. from September 2010 to May 2013, and Riverbed Technology, Inc. from March 2005 to May 2012. He also currently serves on the board, and as audit committee chair, of several private companies. From January 2004 to December 2004, Mr. Meresman was a Venture Partner with Technology Crossover Ventures, a private equity firm, and was General Partner and Chief Operating Officer of Technology Crossover Ventures from November 2001 to December 2003. During the four years before joining Technology Crossover Ventures, he was a private investor and board member and adviser to several technology companies. From May 1989 to May 1997, Mr. Meresman served as the Senior Vice President and Chief Financial Officer of Silicon Graphics, Inc. Mr. Meresman holds a B.S. degree in Industrial Engineering and Operations Research from the University of California, Berkeley and an M.B.A. degree from the Stanford Graduate School of Business.
Chair of the Audit Committee
Member of the Nominating and Corporate Governance Committee
Dipchand Nishar has served as a member of the Guardant Health's board of directors since October 2018. Mr. Nishar has served as the Senior Managing Partner of SoftBank Investment Advisers (US) Inc. since June 2015 and as a member of the board of directors of TripAdvisor, Inc. since September 2013, in addition to currently serving on the boards of directors of several private companies. Previously, he served on the OPower, Inc. board of directors from August 2013 to June 2016. He served as Vice President, Products at LinkedIn Corporation from January 2009 to May 2011 and as Senior Vice President from May 2011 to October 2014. Prior to that, Mr. Nishar served in several roles, including as the senior director of products for the Asia-Pacific region at Google Inc. from August 2003 to January 2009. Mr. Nishar holds an M.B.A. degree from Harvard Business School, an M.S. degree in Electrical Engineering from the University of Illinois, Urbana-Champaign, and a B. Tech degree from the Indian Institute of Technology.
Member of the Compensation Committee